CellRev Secures $14M in Funding to Revolutionize Cell Manufacturing Efficiency!

We are excited to announce that CellRev, a leader in bioprocessing solutions aimed at enhancing the efficiency of cell manufacturing, has successfully raised $14 million in its latest funding round. This significant investment will enable us to continue our mission of transforming the cell culture landscape by addressing critical bottlenecks that impede productivity in various bioprocess protocols. Our innovative product line, which includes our pioneering continuous processing platform, the Livit ACE, is poised to revolutionize adherent cell processing. The funding will allow us to further develop our application-specific intellectual property, enhance our media additives, and bolster our capabilities in supporting customers' journey from discovery to manufacturing. By leveraging this capital, we aim to optimize existing batch, fed-batch, and perfusion-based processes, delivering substantial productivity and cost benefits to our clients. We are committed to providing tailored solutions that cater to the unique needs of our customers, whether they are initiating a new process or refining an existing one. With this latest funding, CellRev is well-positioned to drive innovation in the bioprocessing industry, helping to bring breakthrough treatments to people who need them most. For more information on how our solutions can assist you, please don't hesitate to reach out to us at enquiry@cellrev.co.uk. Thank you for your continued support as we embark on this exciting journey to enhance cell manufacturing processes globally!